Advertisement
Advertisement
U.S. Markets open in 1 hr 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Caladrius Biosciences, Inc. (CLBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7150-0.0150 (-2.05%)
At close: 04:00PM EST
0.7000 -0.01 (-2.10%)
After hours: 06:56PM EST
Advertisement
Sign in to post a message.
  • S
    Sam A
    On CLBS web site the HONDERA trial finished enrolment Q2 2021 and set to report results Q2 2022 and early approval target Q1 2023 so i assume because of COVID the Japanese government must have agreed to limit the number to existing participants being treated so why the company did not make an official announcement? Even on the government web site they updated the dates on December 16, 2021 but no official announcement even then. Very strange this company is very tight lipped.

    https://www.caladrius.com/cd34-cell-therapy-pipeline/critical-limb-ischemia-cli-honedra-clbs12/

    https://clinicaltrials.gov/ct2/show/NCT02501018
  • D
    DT
    According to CLBS the japanese authority has not yet decided if the 4-5 patients needed or not. CLBS is proceeding with existing patients. Hopefuly we find soon what is going on one way or the other. At the same time they are negotiating or looking for a partner. Meanwhile Wallstreet hates this lack of transparency and has punished the stock big time. It is unbelievable a company with $100 mil in the bank to have a Market cap of less than half of that and keep dropping....
  • D
    DT
    Market cap $49 mil. Cash in hand $100 mil.
    What prevents someone buying company at 49-60 mil (+10 mil premium) or bying 51% of stocks in open market and keep the $100 mil in cash after firing everyone else ?
  • P
    Prosperous@2021
    buy back is much faster than i expected. told you guys it was trading less than 1/2 of its cash. i was only able to add an additional 30k shares last month. it still trading for way less than it actual book value. I will continue to try and free up fund and get more. good LONG investment with massive return. only buy what you can afford. super strong Long!
    Bullish
  • M
    Miguel
    huge future
  • R
    Robert
    Big call volume. Breakout on chart....
  • J
    JamJamInvest
    Exciting future ahead, news slowly leaking.
    Bullish
  • R
    Ronald
    1/07/22 Investors should realize that CLBS calculates at $1.65 with cash and cash equivalents with no news as of this time.
    With news, $3.50
  • D
    Darktide
    All that volume for a conference announcement, lol
  • a
    aa
    Another 10% after market
  • S
    Sam A
    Japan trial set to finish ahead of schedule. I guess the Japanese government agreed to speed up this trial. This is great news. But i wonder why the company updated the trial dates today but did not release the news to shareholders. In any case May is less than 6 months away which is excellent.
  • R
    Rafi
    More cash than mcap
    Bullish
  • U
    Uncle A
    Serious program buying today, good sign.
  • C
    CeasarR
    Director just bought 33,785 shares at .90 cents . SEC filing out after the close.

    This is the first buy in years. News must be coming soon
  • T
    Tony
    The trial in Japan was updated. This is Honedra. New study completion date is May 2022. https://clinicaltrials.gov/ct2/show/NCT02501018
  • S
    Saf
    my average is still at 2 😭
  • K
    Kevin
    sid
    Couldn't agree with you more!
    I have read Kristen Buck bio over and over hoping for a change in results. It was discouraging to hear NOTHING has been done in Japan for 18 months. Why not try to partner up earlier? Maybe they did. Any advantage to getting a deal done before the end of year for Japanese company?
  • P
    Prosperous@2021
    oh yeah..load them up.
  • p
    pioneer Seasonal
    Waiting for anything above 2
  • S
    Sam A
    Insider buying is good news for this stock.. Let's hope more insiders buy this week.
Advertisement
Advertisement